IAVI appoints Margaret (Margie) McGlynn President and CEO

The International AIDS Vaccine Initiative (IAVI) announced the appointment of Margaret (Margie) McGlynn as President and CEO. She had been a member of the IAVI Board of Directors since July 2010, and replaces Seth Berkley, IAVI’s Founding President and CEO.  IAVI said that in this role Ms. McGlynn “will be responsible for fostering an environment within IAVI that promotes innovation and flexibility and encourages collaboration with partners, while maintaining a strong commitment to engaging researchers, governments and communities in those countries hardest hit by the pandemic. As President and CEO, McGlynn will serve as an ex-officio member of IAVI’s Board of Directors.”

Ms. McGlynn, who had a 26-year career at Merck and led Merck’s vaccines and infectious diseases business, commented, “I have long been passionate about ensuring that people in the developing world can access life-saving medicines and vaccines, and I am delighted that, in my new role as CEO of IAVI, I will be able to contribute to advancing the search for an effective AIDS vaccine that one day will be available to all of those who need it. I am excited to lead IAVI and work with our partners to build upon the current renaissance in AIDS vaccine research. I look forward to working closely with the Board and senior leadership team to guide IAVI on its mission.” IAVI Founder Seth Berkley, now CEO of the GAVI Alliance, said, “Margie has the right combination of passion, experience and technical understanding to lead IAVI into its next phase. I am confident that IAVI will continue to make a major impact as it pursues its goal of ensuring the development of an AIDS vaccine, and I am secure in the knowledge that I am handing over the reins to an individual as capable and experienced as Margie. I look forward to seeing great things happen at IAVI in the coming years.”